<DOC>
	<DOC>NCT00095264</DOC>
	<brief_summary>The purpose of this study is to assess the effect of 13 weeks of darbepoetin alfa treatment on erythroid response in anemic subjects with low risk Myelodysplastic Syndrome (MDS).</brief_summary>
	<brief_title>A Study of Darbepoetin Alfa in Anemic Subjects With Low Risk Myelodysplastic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Eligibility Criteria: General: Low risk MDS (low or intermediate1 risk as defined by IPSS) and FAB classification of RA, RARS, or RAEB with blasts less than or equal to 10% determined via a bone marrow biopsy and CBC Adequate iron stores determined by bone marrow film or section staining for iron via a bone marrow biopsy ECOG Performance status score of 0, 1, or 2 Laboratory: Local laboratory screening Hgb less than or equal to 11.0g/dL Adequate renal function (serum creatinine concentration less than or equal to 2.0 mg/dL) Adequate liver function (total bilirubin less than or equal to 2 times, ALT less than or equal to 3 times, and AST less than or equal to 3 times the upper limit of the respective normal range) Ethical: Must be 18 years of age or older Provide written Institutional Review Board (IRB)approved informed consent before any screening procedures are performed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>Myelodysplastic Syndrome</keyword>
</DOC>